Riskpilot← Back to searchSign inGet full accessHaga Bioscience AB
ABActiveOrg 5594847864Nobelsväg 16 95:45 Plan 5Research and experimental development on natural sciences and engineering · NACE 7210Est. 20245 employees
Revenue 2025
SEK 0
EBITDA margin
—
-678% vs 2024
Equity ratio
94.8%
Financial strength
Net profit 2025
SEK -4,2M
-677% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -4,2M | -678% |
| Net profit | SEK -4,2M | -677% |
| Total assets | SEK 2,9M | -47% |
| Equity | SEK 2,8M | -47% |
| Employees | 5 | — |
Legal name
Haga Bioscience AB
Org number
5594847864
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27 maj 2024
Share capital
SEK 31 750
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet ska innefatta kommersialisering och utveckling av teknologier för riktad analys av gener och mutationer i biologiska prover med hjälp av mikroskopi sekvensavläsning för biovetenskaplig forskning samt därmed förenlig verksamhet.
Address
Nobelsväg 16 95:45 Plan 5
Email
hower@voxlbio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | −301 | −2 291 |
| EBITDA | −540 | −4 206 |
| Depreciation & amort. | −2 | −8 |
| EBIT | −542 | −4 214 |
| Net financials | 0 | −1 |
| Profit before tax | −542 | −4 215 |
| Tax | — | — |
| Net profit | −542 | −4 215 |
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | 5 469 | 2 918 |
| Equity | 5 233 | 2 767 |
| Long-term debt | — | — |
| Short-term debt | 237 | 151 |
| Total debt | 237 | 151 |
EBITDA margin
-420622900.0%
This company
15.8%
Market median
-2662170353% vs market
20242025
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
20242025
Return on equity
-152.3%
This company
18.4%
Market median
-928% vs market
20242025
Net profit margin
-421514600.0%
This company
8.1%
Market median
-5203884051% vs market
20242025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20242025
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HZ Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2024 | |
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2026 | |
| Former (4) | ||
| Deputy Board Member | 2024 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
| Board of Directors | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Haga Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hao Zhe Lee | Chief Executive Officer | 0 companies |
| Carl Philip Anders Franzén | Deputy Board Member | 0 companies |
| Malte Kühnemund | Chairman | 0 companies |
| Daniel Patrik Gyllborg | Deputy Board Member | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Mats Bo Johan Nilsson Bernitz | Board of Directors | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Carl Christian Krog-Jensen | Board of Directors | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |